Eli Lilly & Co.: Strong Growth Potential and Strategic Innovation Justify Buy Rating

Analyst Asad Haider from Goldman Sachs maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at $883.00.

Asad Haider’s rating is based on several strategic and operational factors that position Eli Lilly & Co. favorably in the market. The company has demonstrated strong demand trends, particularly in the incretin class, which aligns with their 2025 guidance and indicates robust growth potential. Additionally, the management’s proactive approach in engaging with the administration on drug pricing and efforts to reduce out-of-pocket costs for consumers further supports a positive outlook.
Moreover, Eli Lilly’s business development strategy focuses on expanding within core therapeutic areas, with an emphasis on smaller, earlier-stage deals, while not excluding larger opportunities. This strategic focus, along with their interest in the PD1/L1xVEGF bispecific space, suggests a commitment to innovation and growth. Overall, these factors contribute to a reassured perspective on the company’s current state and future prospects, justifying the Buy rating.

According to TipRanks, Haider is a 2-star analyst with an average return of 3.7% and a 66.67% success rate. Haider covers the Healthcare sector, focusing on stocks such as Pfizer, Eli Lilly & Co, and Johnson & Johnson.

In another report released on June 9, Citi also maintained a Buy rating on the stock with a $1,190.00 price target.